Greenwood Capital Associates LLC Biomarin Pharmaceutical Inc Transaction History

Greenwood Capital Associates LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2019 Aug 13, 2019	SELL	$80.35 - $93.9 $497,928 - $581,898	-6,197 Closed	0 $0
Q1 2019 May 03, 2019	BUY	$84.2 - $98.62 $62,729 - $73,471	745 Added 13.66%	6,197 $550,000
Q4 2018 Feb 11, 2019	BUY	$80.14 - $106.07 $63,951 - $84,643	798 Added 17.15%	5,452 $464,000
Q3 2018 Nov 13, 2018	SELL	$93.92 - $105.72 $1,408 - $1,585	-15 Reduced 0.32%	4,654 $451,000
Q2 2018 Aug 07, 2018	BUY	$76.01 - $99.03 $31,544 - $41,097	415 Added 9.76%	4,669 $440,000
Q1 2018 May 15, 2018	BUY	$77.67 - $92.63 $30,679 - $36,588	395 Added 10.24%	4,254 $345,000
Q4 2017 Feb 02, 2018	SELL	$80.76 - $95.13 $151,425 - $178,368	-1,875 Reduced 32.7%	3,859 $344,000
Q3 2017 Nov 03, 2017	BUY	$80.6 - $94.95 $462,160 - $544,443	5,734	5,734 $534,000

637

177M

2.01M

1.28M

Ticker BMRN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,824,000
Market Cap $12.4B
Description
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...

Get notified when there are updates to the investment portfolio of Greenwood Capital Associates LLC, based on Form 13F filings with the SEC.

Stay updated on Greenwood Capital Associates LLC with notifications on news.